Phosphoethanolamine And Omega-3 In Patients With Asthma

dc.creatorPiai
dc.creatorDair B.; Barbeiro
dc.creatorAristoteles; Yonezawa
dc.creatorGisele N.; Quagliato Junior
dc.creatorReynaldo; Neto
dc.creatorSalvador Claro; Chierice
dc.creatorGilberto O.; Moral
dc.creatorRafael A.; Demetrio
dc.creatorClarice G. B.
dc.date2016
dc.date2017-11-13T13:43:20Z
dc.date2017-11-13T13:43:20Z
dc.date.accessioned2018-03-29T05:58:05Z
dc.date.available2018-03-29T05:58:05Z
dc.identifierInternational Journal Of Clinical And Experimental Medicine. E-century Publishing Corp, v. 9, p. 18543 - 18548, 2016.
dc.identifier1940-5901
dc.identifierWOS:000386671100179
dc.identifierhttp://www.ijcem.com/V9_No9.html
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/328537
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1365562
dc.descriptionThe effect of omega-3 (n-3) in asthma has been inconclusive. One explanation for it may be the low incorporation of these fatty acids in clinical studies. Phosphoethanolamine (PEtn) can increase the synthesis of phosphatidylethanolamine, which can, in turn, increase the incorporation of n-3 in cell membranes. The aim of this study is to evaluate the effect of synthetic PEtn in patients with asthma who are receiving n-3. This randomized, double-blind, placebo-controlled study was carried out over a two month period by using spirometry, the Asthma Control Test questionnaire (ACT) and medicine intake. Forty-one patients with asthma were studied. Twenty-one patients received n-3 daily (1.080 mg of EPA, 720 mg of DHA) and 800 mg of PEtn (PEtn group), and twenty patients received the same doses of n-3 and placebo (control group). All patients continued receiving their conventional treatment for asthma. The hospital ethics committee approved the study. Five patients of each group required systemic corticosteroids, being the total consumption, Smaller in the PEtn group (127.4 mg of prednisone/patient versus 416.0 mg of prednisone/patient in the control group, p-value = 0.0269). There were no significant differences in the changing of ATC and FEV1, as well as in the intake of formoterol or budesonide between the groups. In this study, patients who received phosphoethanolamine and omega-3 needed a Smaller dose of systemic corticosteroid for asthma control than patients who only received omega-3. However, as the trial was conducted on a Small scale, more studies are necessary.
dc.description9
dc.description9
dc.description18543
dc.description18548
dc.languageEnglish
dc.publisherE-Century Publishing Corp
dc.publisherMadison
dc.relationInternational Journal of Clinical and Experimental Medicine
dc.rightsaberto
dc.sourceWOS
dc.subjectN-3
dc.subjectOmega-3
dc.subjectPhosphoethanolamine
dc.subjectPhosphatidylethanolamine
dc.subjectAsthma
dc.titlePhosphoethanolamine And Omega-3 In Patients With Asthma
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución